Form 4: BioCryst Pharmaceuticals Director George B. Abercrombie Reports Stock and Option Grant

Director George B. Abercrombie reports acquisition of BioCryst Pharmaceuticals stock and options via automatic non-employee director grants.

Summary

• On June 12, 2024, George B. Abercrombie, a director of BioCryst Pharmaceuticals Inc. [BCRX], reported transactions involving the company's securities.
• Abercrombie acquired 6,820 shares of common stock through an automatic non-employee director grant of Restricted Stock Units (RSUs) at a price of $0, which will vest on June 12, 2025.
• He also received an automatic non-employee director grant of stock options for 49,933 shares with an exercise price of $6.30, exercisable from June 12, 2025, and expiring on June 12, 2034.
• Following these transactions, Abercrombie directly owns 36,431 shares of BioCryst Pharmaceuticals.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices. The alignment of director interests with shareholders is generally viewed favorably.

Positives

• The grant of stock and options to a director aligns their interests with those of the shareholders.
• The vesting schedule of the RSUs and the expiration date of the options encourage long-term commitment.

Industry Context

Director compensation through stock and options is a common practice in the pharmaceutical industry to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard practice in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen (AMGN) and Gilead Sciences (GILD) also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and exercise prices are typically structured to align with long-term value creation for shareholders.

Stakeholder Impact

• The stock and option grants align the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates